Skip to main content
ARIX BIOSCIENCE PLC logo

ARIX BIOSCIENCE PLC — Investor Relations & Filings

Ticker · ARIX ISIN · GB00BD045071 LEI · 213800OVT3AHQCXNIX43 IL Financial and insurance activities
Open in API
Filings indexed 547 across all filing types
Latest filing 2017-02-22 Share Issue/Capital Cha…
Country GB United Kingdom
Listing IL ARIX

About ARIX BIOSCIENCE PLC

https://www.arixbioscience.com/

Arix Bioscience plc is a global venture capital company that specializes in the biotechnology and life sciences sectors. The firm's primary activity involves investing in and building innovative biotech companies, providing capital and strategic support from early stages, including seed, preclinical, and clinical development. Arix focuses on identifying and nurturing breakthrough advances in life sciences to accelerate the development of new medical technologies and therapies. According to public information, the company has entered into a process of liquidation.

Recent filings

Filing Released Lang Actions
Arix Bioscience - admission to trading
Share Issue/Capital Change Classification · 1% confidence The document is identified by the RNS Number (5223X) and the date (22 February 2017), indicating it is a regulatory announcement from a UK-listed company (Arix Bioscience Plc). The content discusses the admission of its ordinary share capital to trading on the London Stock Exchange's main market. It explicitly mentions the 'Prospectus' and refers to the offering of securities, which relates to capital raising or listing activities. While it contains details about share capital and voting rights (which might suggest other types), the primary focus is the announcement of the successful listing/admission following a capital event. This strongly aligns with the 'Capital/Financing Update' (CAP) category, as it details the completion of the process that involved the Prospectus. It is not a full 10-K, an ER, or a simple DIV notice. Given the context of admission to trading following an offering, CAP is the most appropriate fit, although RNS is a close secondary option if the focus was purely on the regulatory filing mechanism itself. Since it details the outcome of a financing/listing event, CAP is preferred over the general RNS fallback.
2017-02-22 English
Stabilisation Notice
Regulatory Filings Classification · 1% confidence The document is identified by the RNS Number (RNS Number : 1350X) and contains a 'Stabilisation Notice' dated 17 February 2017, detailing the potential stabilization activities related to an offering of Ordinary Shares by Arix Bioscience plc. This type of announcement, which relates to market activities surrounding an offering (stabilization, over-allotment options) and is disseminated via the London Stock Exchange's regulatory news service (RNS), fits best under the general 'Regulatory Filings' category, as it is not a core financial report (10-K, IR), an earnings release (ER), or a specific management/board change (MANG, DIRS). While it is a specific type of announcement, RNS serves as the appropriate catch-all for such regulatory market notices that don't fit the other specific codes.
2017-02-17 English
Arix Bioscience raises £100m in IPO
Regulatory Filings Classification · 1% confidence The document is an official announcement regarding the successful completion of an Initial Public Offering (IPO) by Arix Bioscience plc. It details the capital raised (£100 million), the number of shares issued, the market capitalization, and the commencement of trading on the London Stock Exchange. While it discusses capital, it is specifically an announcement of a new share issuance and IPO completion, which falls under the category of Share Issue/Capital Change (SHA).
2017-02-17 English
Issuer Document
Capital/Financing Update Classification · 1% confidence The document explicitly identifies itself as a "PROSPECTUS" dated February 2, 2017. It details an offering of new ordinary shares and has been prepared in accordance with the Prospectus Rules of the UK Financial Conduct Authority (FCA). A prospectus is a formal legal document required for public offerings of securities, providing detailed information to potential investors. This aligns most closely with documents related to capital raising or financing activities, which falls under the 'Capital/Financing Update' category (CAP). While it contains extensive information similar to an Annual Report, its primary function here is to facilitate a share offering, making CAP the most precise fit among the provided options, as it is a document used for a capital event.
2017-02-02 English
Resolutions
AGM Information Classification · 1% confidence The document explicitly states it contains the 'RESOLUTIONS OF ARIX BIOSCIENCE PLC (THE "COMPANY") (Passed 5 June 2017)' from an 'Annual General Meeting'. It details various Ordinary and Special Resolutions concerning Directors' Remuneration Policy, authority to allot shares, disapplication of pre-emption rights, authority to purchase ordinary shares, and authority to re-purchase and cancel own Deferred Shares. This content is characteristic of the formal documentation presented or voted upon at an Annual General Meeting (AGM). Therefore, the appropriate classification is AGM-R (AGM Information).
2016-12-31 English
Notice of AGM
AGM Information Classification · 1% confidence The document explicitly states 'Notice of the 2017 Annual General Meeting' in the title and repeatedly refers to the 'AGM' throughout the text. It details the date, time, location, and the specific resolutions shareholders are asked to vote on, which is the core content of a notice for an Annual General Meeting. This aligns perfectly with the definition for AGM Information (AGM-R). Although it contains elements that might be found in an Annual Report (like receiving accounts), the primary purpose and structure of this document is the formal notice and invitation to the meeting itself.
2016-12-31 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.